Similarities and Differences Between Patients Diagnosed with ANCA-Associated Vasculitis Who Are Positive and Negative for ANCA: University Clinic Practice and Expertise
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Mukhtyar, C.; Guillevin, L.; Cid, M.C.; Dasgupta, B.; de Groot, K.; Gross, W.; Hauser, T.; Hellmich, B.; Jayne, D.; Kallenberg, C.G.M.; et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann. Rheum. Dis. 2009, 68, 310–317. [Google Scholar] [CrossRef]
- Jennette, J.C.; Falk, R.J.; Bacon, P.A.; Basu, N.; Cid, M.C.; Ferrario, F.; Flores-Suarez, L.F.; Gross, W.L.; Guillevin, L.; Hagen, E.C.; et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013, 65, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Millet, A.; Pederzoli-Ribeil, M.; Guillevin, L.; Witko-Sarsat, V.; Mouthon, L. Republished: Antineutrophil cytoplasmic antibody-associated vasculitides: Is it time to split up the group? Postgrad. Med. J. 2014, 90, 290–296. [Google Scholar] [CrossRef] [PubMed]
- Miloslavsky, E.M.; Lu, N.; Unizony, S.; Choi, H.K.; Merkel, P.A.; Seo, P.; Spiera, R.; Langford, C.A.; Hoffman, G.S.; Kallenberg, C.G.; et al. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients with Granulomatosis with Polyangiitis (Wegener’s): Distinct Patient Subsets. Arthritis Rheumatol. 2016, 68, 2945–2952. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Fijolek, J.; Radzikowska, E. Eosinophilic granulomatosis with polyangiitis—Advances in pathogenesis, diagnosis, and treatment. Front. Med. 2023, 10, 1145257. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Pearce, F.A.; Craven, A.; Merkel, P.A.; Luqmani, R.A.; Watts, R.A. Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology 2017, 56, 1962–1969. [Google Scholar] [CrossRef] [PubMed]
- Furuta, S.; Chaudhry, A.N.; Hamano, Y.; Fujimoto, S.; Nagafuchi, H.; Makino, H.; Matsuo, S.; Ozaki, S.; Endo, T.; Muso, E.; et al. Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J. Rheumatol. 2014, 41, 325–333. [Google Scholar] [CrossRef] [PubMed]
- Furuta, S.; Chaudhry, A.N.; Arimura, Y.; Dobashi, H.; Fujimoto, S.; Homma, S.; Rasmussen, N.; Jayne, D.R. Comparison of the Phenotype and Outcome of Granulomatosis with Polyangiitis Between UK and Japanese Cohorts. J. Rheumatol. 2017, 44, 216–222. [Google Scholar] [CrossRef] [PubMed]
- Flossmann, O.; Berden, A.; de Groot, K.; Hagen, C.; Harper, L.; Heijl, C.; Höglund, P.; Jayne, D.; Luqmani, R.; Mahr, A.; et al. European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 2011, 70, 488–494. [Google Scholar] [CrossRef] [PubMed]
- Jardel, S.; Puéchal, X.; Le Quellec, A.; Pagnoux, C.; Hamidou, M.; Maurier, F.; Aumaitre, O.; Aouba, A.; Quemeneur, T.; Subra, J.F.; et al. French Vasculitis Study Group (FVSG). Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. Autoimmun. Rev. 2018, 17, 653–659. [Google Scholar] [CrossRef] [PubMed]
- Tan, J.A.; Dehghan, N.; Chen, W.; Xie, H.; Esdaile, J.M.; Avina-Zubieta, J.A. Mortality in ANCA-associated vasculitis: Ameta-analysis of observational studies. Ann. Rheum. Dis. 2017, 76, 1566–1574. [Google Scholar] [CrossRef]
- Mukhtyar, C.; Flossmann, O.; Hellmich, B.; Bacon, P.; Cid, M.; Cohen-Tervaert, J.W.; Gross, W.L.; Guillevin, L.; Jayne, D.; Mahr, A.; et al. European Vasculitis Study Group (EUVAS). Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: A systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann. Rheum. Dis. 2008, 67, 1004–1010. [Google Scholar] [CrossRef] [PubMed]
- Robson, J.C.; Grayson, P.C.; Ponte, C.; Suppiah, R.; Craven, A.; Judge, A.; Khalid, S.; Hutchings, A.; Watts, R.A.; Merkel, P.A.; et al. DCVAS Investigators. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann. Rheum. Dis. 2022, 81, 315–320. [Google Scholar] [CrossRef] [PubMed]
- Suppiah, R.; Robson, J.C.; Grayson, P.C.; Ponte, C.; Craven, A.; Khalid, S.; Judge, A.; Hutchings, A.; Merkel, P.A.; Luqmani, R.A.; et al. DCVAS INVESTIGATORS. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann. Rheum. Dis. 2022, 81, 321–326. [Google Scholar] [CrossRef] [PubMed]
- Grayson, P.C.; Ponte, C.; Suppiah, R.; Robson, J.C.; Craven, A.; Judge, A.; Khalid, S.; Hutchings, A.; Luqmani, R.A.; Watts, R.A.; et al. DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann. Rheum. Dis. 2022, 81, 309–314. [Google Scholar] [CrossRef] [PubMed]
- Bossuyt, X.; Cohen Tervaert, J.W.; Arimura, Y.; Blockmans, D.; Flores-Suárez, L.F.; Guillevin, L.; Hellmich, B.; Jayne, D.; Jennette, J.C.; Kallenberg, C.G.M.; et al. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat. Rev. Rheumatol. 2017, 13, 683–692. [Google Scholar] [CrossRef]
- Pyo, J.Y.; Lee, L.E.; Park, Y.B.; Lee, S.W. Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria. Yonsei Med. J. 2023, 64, 11–17. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Eisenberger, U.; Fakhouri, F.; Vanhille, P.; Beaufils, H.; Mahr, A.; Guillevin, L.; Lesavre, P.; Noël, L.H. ANCA-negative pauci-immune renal vasculitis: Histology and outcome. Nephrol. Dial. Transplant. 2005, 20, 1392–1399. [Google Scholar] [CrossRef] [PubMed]
- Jennette, J.C.; Nachman, P.H. ANCA Glomerulonephritis and Vasculitis. Clin. J. Am. Soc. Nephrol. 2017, 12, 1680–1691. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Watts, R.; Lane, S.; Bentham, G.; Scott, D. Epidemiology of systemic vasculitis: A ten-year study in the united kingdom. Arthritis Rheum. 2000, 43, 414–419. [Google Scholar] [CrossRef]
- Zhao, W.M.; Wang, Z.J.; Shi, R.; Zhu, Y.Y.; Zhang, S.; Wang, R.F.; Wang, D.G. Environmental factors influencing the risk of ANCA-associated vasculitis. Front. Immunol. 2022, 13, 991256. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Korsten, P.; Baier, E.; Hakroush, S.; Tampe, B. C-Reactive Protein Levels Are Associated with Complement C4 Deposits and Interstitial Arteritis in ANCA-Associated Renal Vasculitis. Int. J. Mol. Sci. 2023, 24, 3072. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kemna, M.J.; Damoiseaux, J.; Austen, J.; Winkens, B.; Peters, J.; van Paassen, P.; Cohen Tervaert, J.W. ANCA as a predictor of relapse: Useful in patients with renal involvement but not in patients with nonrenal disease. J. Am. Soc. Nephrol. 2015, 26, 537–542. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Almaani, S.; Fussner, L.A.; Brodsky, S.; Meara, A.S.; Jayne, D. ANCA-Associated Vasculitis: An Update. J. Clin. Med. 2021, 10, 1446. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Houben, E.; Bax, W.A.; van Dam, B.; Slieker, W.A.T.; Verhave, G.; Frerichs, F.C.P.; van Eijk, I.C.; Boersma, W.G.; de Kuyper, G.T.M.; Penne, E.L. Diagnosing ANCA-associated vasculitis in ANCA positive patients: A retrospective analysis on the role of clinical symptoms and the ANCA titre. Medicine 2016, 95, e5096. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Wawrzycka-Adamczyk, K.; Korkosz, M.; Musiał, J.; Wójcik, K. Relapse Predictors in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. Diagnostics 2024, 14, 1849. [Google Scholar] [CrossRef]
- Roth, A.J.; Ooi, J.D.; Hess, J.J.; van Timmeren, M.M.; Berg, E.A.; Poulton, C.E.; McGregor, J.; Burkart, M.; Hogan, S.L.; Hu, Y.; et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J. Clin. Investig. 2013, 123, 1773–1783. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- FijoŁek, J.; Wiatr, E. Antineutrophil cytoplasmic antibodies (ANCA)—Their role in pathogenesis, diagnosis, and treatment monitoring of ANCA-associated vasculitis. Cent. Eur. J. Immunol. 2020, 45, 218–227. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Deshayes, S.; Martin Silva, N.; Khoy, K.; Yameogo, S.; Mariotte, D.; Lobbedez, T.; Aouba, A. Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology 2019, 58, 1731–1739. [Google Scholar] [CrossRef] [PubMed]
ANCA+ | ANCA− | |||
---|---|---|---|---|
MPO+ or p-ANCA | PR3+ or c-ANCA | Undifferentiated ANCA | ||
GPA according to 2012 Chapel Hill consensus criteria, n = 40 (%) | 3 (7.5) | 24 (60) | 1 (2.5) | 12 (30) |
MPA according to 2012 Chapel Hill consensus criteria, n = 17 (%) | 8 (47.1) | 5 (29.4) | 1 (5.9) | 3 (17.6) |
EGPA according to 2012 Chapel Hill consensus criteria, n = 16 (%) | 2 (12.5) | 4 (25) | . | 10 (62.5) |
ANCA+ (PR3-ANCA, c-ANCA or MPO-ANCA, p-ANCA) | ANCA− | p-Value | |
---|---|---|---|
Demographic characteristics | |||
Female, n (%) | 32 (66.7) | 17 (68.0) | |
Male, n (%) | 16 (33.3) | 8 (32.0) | |
Mean age at diagnosis (±SD) | 48.8 (±11.9) | 48.5 (±14.4) | |
Median age at the time of diagnosis | 51 | 48 | |
Clinical manifestation | |||
Pulmonary involvement, n (%) | 41 (85.4) | 22 (88.0) | 0.7607 |
Kidney involvement n (%) | 29 (60.4) | 6 (24.0) | 0.0031 |
Kidney biopsies performed n (%) | 25 (52.1) | 5 (20) | 0.0082 |
ENT involvement n (%) | 37 (77.1) | 23 (92.0) | 0.1139 |
Skin involvement n (%) | 12 (25.0) | 7 (28.0) | 0.7816 |
Joint involvement n (%) | 19 (39.6) | 11 (44.0) | 0.7150 |
St. aureus from the swab n (%) | 7 (14.6) | 4 (16.0) | 0.8724 |
Neurological involvement n (%) | 14 (29.2) | 5 (20) | 0.3970 |
Laboratory tests | |||
Serum CRP level, mg/L | 0.3457 | ||
Median | 33.5 | 21.0 | |
Minimum | 0.3 | 0.2 | |
Maximum | 279.0 | 310.0 | |
ESR, mm/h | 0.96 | ||
Median | 51.5 | 42.5 | |
Minimum | 2 | 5 | |
Maximum | 120 | 120 | |
WBC | 0.5226 | ||
Average (±SD) | 11.24 (±8.5) | 10.23 (±3.9) | |
Median | 9.1 | 9.6 | |
Minimum | 2.9 | 4.6 | |
Maximum | 45.7 | 18.6 | |
Hemoglobin, g/L | 0.00007 | ||
Average (±SD) | 106 (±18.2) | 127 (±19.9) | |
Median | 106 | 130 | |
Minimum | 70 | 81 | |
Maximum | 137 | 167 | |
Serum creatinine level, µmol/L | 0.058 | ||
Median | 93.5 | 70.0 | |
Minimum | 33 | 58 | |
Maximum | 1058 | 493 |
GPA | MPA | EGPA | ||||
---|---|---|---|---|---|---|
ANCA+ | ANCA− | ANCA+ | ANCA− | ANCA+ | ANCA− | |
Demographic characteristics | ||||||
Female, n (%) | 20 (71.4) | 7 (58.3) | 8 (57.1) | 3 (100) | 4 (66.7) | 7 (70) |
Male, n (%) | 8 (28.6) | 5 (41.6) | 6 (42.9) | 0 (0) | 2 (33.3) | 3 (30) |
Mean age at diagnosis | 48.14 | 48.89 | 47.45 | 56.52 | 54.84 | 45.63 |
Median age at the time of diagnosis | 51 | 48 | 51 | 49 | 50 | 48 |
Clinical manifestation | ||||||
Pulmonary involvement, n (%) | 27 (96.4) | 11 (91.7) | 9 (64.3) | 2 (66.7) | 5 (83.3) | 9 (90) |
Kidney involvement, n (%) | 16 (57.1) | 3 (25) | 13 (92.9) | 3 (100) | 0 (0) | 0 (0) |
ENT involvement, n (%) | 26 (92.9) | 12 (100) | 6 (42.9) | 3 (100) | 5 (83.3) | 8 (80) |
Skin involvement, n (%) | 7 (25) | 0 (0) | 4 (28.6) | 2 (66.7) | 1 (16.7) | 5 (50) |
Joint involvement, n (%) | 12 (42.9) | 4 (33.3) | 5 (35.7) | 1 (33.3) | 2 (33.3) | 6 (60) |
Neurological involvement, n (%) | 6 (21.4) | 2 (16.7) | 4 (28.6) | 1 (33.3) | 4 (66.7) | 2 (20) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Dereseviciene, G.; Dadoniene, J.; Miltiniene, D. Similarities and Differences Between Patients Diagnosed with ANCA-Associated Vasculitis Who Are Positive and Negative for ANCA: University Clinic Practice and Expertise. Medicina 2025, 61, 1369. https://doi.org/10.3390/medicina61081369
Dereseviciene G, Dadoniene J, Miltiniene D. Similarities and Differences Between Patients Diagnosed with ANCA-Associated Vasculitis Who Are Positive and Negative for ANCA: University Clinic Practice and Expertise. Medicina. 2025; 61(8):1369. https://doi.org/10.3390/medicina61081369
Chicago/Turabian StyleDereseviciene, Giedre, Jolanta Dadoniene, and Dalia Miltiniene. 2025. "Similarities and Differences Between Patients Diagnosed with ANCA-Associated Vasculitis Who Are Positive and Negative for ANCA: University Clinic Practice and Expertise" Medicina 61, no. 8: 1369. https://doi.org/10.3390/medicina61081369
APA StyleDereseviciene, G., Dadoniene, J., & Miltiniene, D. (2025). Similarities and Differences Between Patients Diagnosed with ANCA-Associated Vasculitis Who Are Positive and Negative for ANCA: University Clinic Practice and Expertise. Medicina, 61(8), 1369. https://doi.org/10.3390/medicina61081369